Abstract 2089P
Background
Febrile neutropenia (FN) resulting from myelosuppressive chemotherapy drugs, have the potential to necessitate dose reduction or treatment delays, thus compromising the overall efficacy of treatment. This study aims to analyze the incidence of FN and related adverse drug reactions in cancer patients who receive prophylaxis with PEG-rhG-CSF (a long-acting granulocyte colony-stimulating factor).
Methods
This real-world study was conducted as a multicenter, retrospective, observational research involving adult cancer patients who received chemotherapy with PEG-rhG-CSF prophylactic. The study focused on several variables, including baseline characteristics and incidence of FN. Descriptive analysis was performed by using IBM SPSS Statistics 27.
Results
24,199 patients were enrolled from 575 hospitals across China between June 2022 and January 2023. The chemotherapy cycle records encompassed 1to 20 cycle. Among the enrolled patients, breast cancer was the most prevalent tumor type, accounting for 33.6% (N=8,131) of the cases. FN incidence across all cycles was 0.054% and it was 0.055% and 0.053% among patients receiving PEG-rhG-CSF as primary and secondary prophylaxis. These rates were significantly lower than the previously reported data of 13% to 21% from a retrospective cohort study involving patients with or without prophylaxis. Overall, FN occurred across the first to eighth cycles with the highest incidence observed in cycle 1 (52.50%). 1,659 records (2.25%) reported adverse events related to PEG-rhG-CSF. The most commonly observed adverse effect was musculoskeletal pain, accounting for 1.53% of the cases, followed by fatigue(0.60%) and allergic reactions(0.07%). Furthermore, 90.78% of adverse reactions were categorized as primary or secondary adverse reactions.
Conclusions
Under PEG-rhG-CSF prophylaxis, cancer patients exhibited a low incidence of FN which primarily occurred in the initial cycle of chemotherapy. Importantly, the administration of PEG-rhG-CSF was well tolerated.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
2065P - Communication on the first medical oncology appointment: What do cancer patients want?
Presenter: Rodrigo Vicente
Session: Poster session 06
2066P - Evaluation of the quality and reliability of ChatGPT and Perplexity's responses about rectal cancer
Presenter: Ozan Yazici
Session: Poster session 06
2067P - Influence of psychiatric disorders on survival in patients with lung cancer: Real-world data
Presenter: Tomi Kovacevic
Session: Poster session 06
2068P - Perspectives and concerns on sexuality among adolescents and young adults treated for testicular germ cell tumour: The PRICELESS-study - A qualitative study
Presenter: Danielle Zweers
Session: Poster session 06
2069P - QoL changes of caregivers during first-line palliative chemotherapy for patients with incurable cancer
Presenter: Nobumichi Takeuchi
Session: Poster session 06
2070P - Assessment of healthy lifestyle habits in breast cancer patients
Presenter: Juan Cristobal Sanchez
Session: Poster session 06
2071P - Identification of top issues and concerns of cancer patients in Korea on social media
Presenter: Joo Han Lim
Session: Poster session 06
2072P - Topical application of mixed agents to reduce oral mucositis during radiotherapy in post operated head and neck cancer
Presenter: Chandra Prakash
Session: Poster session 06
2073P - Medical cannabis: A potential effective treatment for chemotherapy-induced peripheral neuropathy (CIPN)
Presenter: Ravit Geva
Session: Poster session 06
2074P - Oral cannabidiol for prevention of chemotherapy-induced peripheral neuropathy
Presenter: Sebastian Nielsen
Session: Poster session 06